Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Caribou Biosciences Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data, during Q4, Caribou Biosciences (NASDAQ:CRBU) posted sales of $2.56 million. Earnings were up 11.9%, but Caribou Biosciences still reported an overall loss of $18.48 million. Caribou Biosciences collected $3.98 million in revenue during Q3, but reported earnings showed a $20.97 million loss.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.